A second Phase III study from Incyte’s (Nasdaq: INCY) TRuE-AD clinical trial program in mild-to-moderate atopic dermatitis (AD) has met its primary endpoint.
Following on from the positive top-line results from TRuE-AD2, the results of TRuE-AD1 also show that significantly more patients treated with ruxolitinib (trade name Jakafi) cream 0.75% or 1.5% achieved investigator’s global assessment treatment success.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze